Hi Diamo. RAP has always positioned it's technology as diagnostic however as can be seen from their clinical results (the proper one's not the one's they gamed in WA trials), that is has struggled to do that with any confidence and accuracy. It is also only an "indicative" result (look at their presentations and the screen shot of their results always says it indicates pneumonia only) meaning that the patient will still have to go to a Doctor to undergo a lung function, spirometry etc to get a full and comprehensive diagnosis. RAP also only focuses on cough which is not a primary symptom of chronic respiratory disease, whereas wheeze is a primary symptom and acknowledged by healthcare professionals/doctors which is why Wheezo will be so powerful and beneficial and bring in the new world of wheezometry! Wheezo will not need a 2nd opinion to validate the results as this has already been achieved from the clinical trials in Chicago and ongoing testing. Why do you think Professor Bruce Thompson and Professor Francis Thien have put their names to Wheezo/RSH and not RAP....speaks volumes in the healthcare professional world, RAP is still a long shot at best.
RSH Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
